Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/27773
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 16812/19099 (88%)
造访人次 : 6890367      在线人数 : 969
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.cnu.edu.tw/handle/310902800/27773


    標題: An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA
    作者: Yen, M-C
    Weng, T-Y
    Chen, Y-L
    Lin, C-C
    Chen, C-Y
    Wang, C-Y
    Chao, H-L
    Chen, C-S
    Lai, M-D
    貢獻者: 老人服務事業管理系
    關鍵字: H1 Promoter
    Ido Shrna
    Indoleamine 2,3-Dioxygenase
    Osu-Hdac42
    Rna Polymerase Iii
    U6 Promoter
    日期: 2013-06
    上傳時間: 2014-05-26 10:43:05 (UTC+8)
    出版者: Nature Publishing Group
    摘要: Histone deacetylase (HDAC) inhibitors are used in treating certain human malignancies. Our laboratories demonstrated their capability in enhancing antitumor effect of DNA vaccine driven by an RNA polymerase II (RNA pol II) promoter. However, it is unknown whether HDAC inhibitors enhance the therapeutic short hairpin RNA (shRNA) expressed by an RNA polymerase III (RNA pol III) promoter. We investigated whether HDAC inhibitors augmented antitumor effect of indoleamine 2,3 dioxygenase (IDO) shRNA. HDAC inhibitor OSU-HDAC42 and suberoylanilide hydroxamic acid enhanced RNA pol III-driven U6 and H1 promoter activity in three different cell types in vitro: 293, NIH3T3 and dendritic cell line DC2.4. Subcutaneous injection of OSU-HDAC42 enhanced U6 and H1 promoter activity on abdominal skin of mice in vivo. Combination of IDO shRNA and OSU-HDAC42 increased antitumor effect of IDO shRNA in MBT-2 murine bladder tumor model. IDO shRNA induced tumor-infiltrating CD8(+) and CD4(+) T cells, whereas OSU-HDAC42 treatment induced tumor-infiltrating CD4(+) T cells. Combination of OSU-HDAC42 and IDO shRNA further induced tumor-infiltrating natural killer cells and enhanced interferon-gamma in lymphocytes, but suppressed interleukin (IL)-4 expression of lymphocytes. In addition, OSU-HDAC42 treatment did not alter mRNA expression of IL-12 and tumor necrosis factor-alpha. In conclusion, HDAC inhibitor OSU-HDAC42 may serve as adjuvant of the therapeutic shRNA expressed by an RNA pol III promoter.
    關聯: Cancer Gene therapy, v.20 n.6, pp.351-357
    显示于类别:[老人服務事業管理系] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML692检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈